Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-30 @ 1:27 AM
Study NCT ID:
NCT07482657
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-19
First Post:
2026-03-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Sponsor:
Enanta Pharmaceuticals, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-07
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12
Completion Date Type:
ESTIMATED
First Submit Date:
2026-03-16
First Submit QC Date:
None
Study First Post Date:
2026-03-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-03-16
Last Update Post Date:
2026-03-19
Last Update Post Date Type:
ACTUAL